The Investment Column: Business as usual at Amersham
Wednesday 12 November 1997
Since the Norwegian tie-up was announced in early July, shares in Amersham have soared by a third. Yesterday's first results since that deal - interims from Amersham and third quarters from Nycomed - pushed the price up another 27.5p to 2222.5p.
The numbers themselves offer no real guide to the shape of the new company. The Nycomed deal was only cemented two and a half weeks ago and chief Bill Castell says it is too early to confirm estimates of pounds 40m a year cost savings. What the numbers did do is reassure that, despite the deal, it is business as usual for both companies.
Amersham's new Pharmacia business, supplying chemicals used in drug company research, looks a good buy. In just two months it contributed pounds 6m, driving sales in the half year at Amersham's Life Science division 65 per cent ahead to pounds 122m at constant currency and profits 55 per cent ahead to pounds 22m. Cost savings of pounds 30m a year over a three-year period should be possible.
On the Healthcare side, even excluding acquisitions, profits rose 58 per cent, driven by growing demand for Myoview, the heart-imaging agent, and the iodine seed treatment for prostate cancer.
Integrating Nycomed will be a big and potentially disruptive job, though Mr Castell insists morale is high. Commercially the acquisition makes great sense, giving Amersham a full range of imaging agents and innovations like ultrasound. Concern over price pressure in Nycomed's core US contrast media agent business remain, though Nycomed's cost reduction plan looks on track. At current levels, the shares trade on over 20 times earnings. Until the group presents integrated figures next March, that looks high enough, particularly given the inevitable disruption associated with a large merger.
filmNymphomaniac is more Carl Dreyer than sexploitation of Russ Meyer
elephant appealThe first 23 lots in our charity auction have now gone. But there are 22 more still up for grabs
scienceScientists find the answer to a question that even puzzled Darwin
arts + entsThe 'Friends' actor on his new role as campaigner on addiction issues
Geoffrey Macnab: The Wolf of Wall Street's account of white-collar excess is A Rake’s Progress on steroids
scienceThe new development in bio-printing technology could be used in the future to restore lost vision - though years of research still await
architectureThe design collective which has stuck two fingers up at the modernists will call it quits at Venice
... But if you’re one of those poor souls offended by Jennifer Lopez’s choice of leotard, Grace Dent want you to get a bloody grip
Sun will 'flip upside down' within weeks, says Nasa
Colin Farrell reveals ‘affair’ with Elizabeth Taylor: 'She was my last romantic relationship'
Children evacuated from swimming pool after prosthetic leg mistaken for paedophile
India-US row over escalates over arrest of diplomat Devyani Khobragade in New York
Peter O'Toole: Tales of the late film icon
- 1 Facebook 'self-censorship': study records when you don't post to find more ways to share
- 2 Sun will 'flip upside down' within weeks, says Nasa
- 3 British prisoner Dr Abbas Khan found dead in Syrian jail days before he was due to be handed over to MP George Galloway
- 4 Vitamin pills are a waste of money, offer no health benefits and could be harmful - study
- 5 Children evacuated from swimming pool after prosthetic leg mistaken for paedophile
- < Previous
- Next >
iJobs Money & Business
£50000 - £75000 per annum + benefits + bonus: Harrington Starr: Implementation...
£50000 - £65000 per annum + benefits + bonus: Harrington Starr: Project Manage...
Negotiable: Harrington Starr: My client deliver into the Investment Managemen...
£25000 - £35000 per annum + Bonus and Benefits: Harrington Starr: Harrington S...